Peregrine Pharmaceuticals (NASDAQ: PPHM ) will report second quarter results after the bell today, and given that shares have done little this year, investors are right to be looking for clues as to when the company's promising immunotherapy drug for cancer may make an impact.
In the following slideshow, I offer insight into Peregrine's bavituximab and outline key questions I'll be looking to have answered during the second quarter conference call.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.